Companies/Theralase Technologies Inc.

Company profile

Theralase Technologies Inc.

OTC: TLTFF · Healthcare · Medical - Devices

Canadian filerHQ Toronto, ONReports USD

#915 of 1,394 Healthcare companies by revenue27th-percentile growth

EA Score

37D

FH 33DQ —GM 42SS 53

v0.1 · 45/100 weight · provisional

↑ growth stability, listing tenure · ↓ return on equity, Piotroski F

Methodology →

Revenue TTM

$620.6k

Rev growth YoY (TTM)

-9.4%

Net income (FY)

-$2.9M

Employees

Market cap

$53.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$584.1k816.5k CAD2025

Net income-$2.9M-4.1M CAD2025

Operating income-$3.0M-4.2M CAD2025

Total assets$2.5M3.5M CAD2025

Liabilities$1.3M1.7M CAD2025

Equity$1.3M1.8M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$1.3M

FY18

$726.5k

FY19

$692.7k

FY20

$622.7k

FY21

$875.1k

FY22

$793.0k

FY23

$754.4k

FY24

$584.1k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Theralase Technologies Inc. booked $584.1k in FY2025 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -504.7% net margin.

Peers · Healthcare

DarioHealth Corp.50D Instil Bio, Inc.36D Daxor Corporation——Acrivon Therapeutics, Inc. Common Stock——

Key facts

CEORoger John Dumoulin-White

SectorHealthcare

IndustryMedical - Devices

HeadquartersToronto, ON

ExchangeOTC: TLTFF

Employees14

IPO date2010-04-05

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.